The Role of Cell Cycle Arrest Biomarkers for Predicting Acute Kidney Injury in Critically Ill COVID-19 Patients: A Multicenter, Observational Study.

Fecha de publicación: 01/08/2023 Fecha Ahead of Print: 28/03/2023

Autores de IIS La Fe

María Jesús Broch Porcar

Autor

Participantes ajenos a IIS La Fe

Weiss R
von Groote T
Ostermann M
Lumlertgul N
Weerapolchai K
Garcia MIM
Cano JMM
Del Corral BD
Perez Carrasco M
De la Vega Sanchez A
Sousa E
Catarino A
Roig AJB
Martinez de Irujo JB
de Rosa S
de la Peña MG
Tomasa T
Brivio M
De Molina FJG
Gerss J
Kellum JA
Wempe C
Leidereiter A
Meersch M
Zarbock A

Grupos

Medicina Intensiva

Abstract

OBJECTIVES: Patients with COVID-19-associated acute respiratory distress syndrome (ARDS) have a high risk for developing acute kidney injury (AKI) which is associated with an increased risk of death and persistent renal failure. Early prediction of AKI is crucial in order to implement preventive strategies. The purpose of this study was to investigate the predictive performance of tissue inhibitor of metalloproteinases 2 and insulin like growth factor binding protein 7 (TIMP-2) × (IGFBP7) in critically ill patients with COVID-19-associated ARDS. DESIGN: Multicenter, prospective, observational study. SETTING: Twelve centers across Europe and United Kingdom. PATIENTS: Patients with moderate or severe COVID-19-associated ARDS were included and serial measurements of (TIMP-2) × (IGFBP7) were performed. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The primary endpoint was the development of moderate or severe AKI according to the Kidney Disease: Improving Global Outcomes definition. Three hundred patients were available for the primary analysis, and 39 met the primary endpoint. At enrollment, urinary (TIMP-2) × (IGFBP7) had high predictive value for the primary endpoint with an area under the receiver operating characteristic curve of 0.89 (95% CI, 0.84-0.93). (TIMP-2) × (IGFBP7) was significantly higher in endpoint-positive patients at enrollment and at 12 hours. CONCLUSIONS: Urinary (TIMP-2) × (IGFBP7) predicts the occurrence of AKI in critically ill patients with COVID-19-associated ARDS.

Datos de la publicación

ISSN/ISSNe:: 0090-3493, 1530-0293
Tipo:: Article
Páginas:: 992-1000
DOI:: 10.1097/CCM.0000000000005853
PubMed:: 36975308
Enlace a otro recurso:: www.scopus.com
Factor de Impacto:: 2,689 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Weiss R:: Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, University Hospital Münster, Münster, Germany
von Groote T:: Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, University Hospital Münster, Münster, Germany
Ostermann M:: Department of Critical Care, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom
Lumlertgul N:: Department of Critical Care, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom

Division of Nephrology, Department of Internal Medicine and Excellence Centre in Critical Care Nephrology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

Centre of Excellence in Critical Care Nephrology, Division of Nephrology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Weerapolchai K:: Department of Critical Care, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom

Division of Urology, Royal Thai Navy, Somdech Phra Pinklao Hospital, Bangkok, Thailand
Garcia MIM:: Department of Critical Care Medicine, University Hospital SAS de Jerez, Jerez de la Frontera, Spain
Cano JMM:: Department of Critical Care Medicine, University Hospital SAS de Jerez, Jerez de la Frontera, Spain
Del Corral BD:: Department of Critical Care Medicine, University Hospital SAS de Jerez, Jerez de la Frontera, Spain
Broch-Porcar MJ:: Department of Critical Care, Hospital La Fe, Valencia, Spain
Perez Carrasco M:: Critical Care Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain

Spain

Shock, Organ Dysfunction and Resuscitation (SODIR), Critical Care Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
De la Vega Sanchez A:: Critical Care Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
Sousa E:: Department of Critical Care, Centro Hospitalare e Universitario de Coimbra, Coimbra, Portugal
Catarino A:: Department of Critical Care, Centro Hospitalare e Universitario de Coimbra, Coimbra, Portugal
Roig AJB:: Department of Critical Care Medicine, Hospital Sant Pau, Barcelona, Spain
Martinez de Irujo JB:: Department of Critical Care Medicine, Hospital Sant Pau, Barcelona, Spain
de Rosa S:: Department of Anesthesia and Intensive Care, San Bortolo Hospital, Vicenza, Italy
de la Peña MG:: Department of Intensive Care, Complejo Hospitalario de Navarra, Navarra, Spain
Tomasa T:: Department of Intensive Care, Hospital Germans Trias I Pujol, Barcelona, Spain
Brivio M:: Emergency and Critical Care Medicine Department, Papa Giovanni XXIII Hospital, Bergamo, Italy
De Molina FJG:: Department of Critical Care Medicine, Hospital Universitario Mutua Terrasa, Barcelona, Spain
Gerss J:: Institute of Biostatistics and Clinical Research, Medical Faculty, University of Münster, Münster, Germany
Wempe C:: Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, University Hospital Münster, Münster, Germany
Leidereiter A:: Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, University Hospital Münster, Münster, Germany
Meersch M:: Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, University Hospital Münster, Münster, Germany
Zarbock A:: Department of Anesthesiology, Intensive Care Medicine and Pain Medicine, University Hospital Münster, Münster, Germany

Keywords

acute kidney injury; biomarkers; cell cycle arrest biomarkers; COVID-19; lung injury; tissue inhibitor of metalloproteinases 2 and insulin like growth factor binding protein 7